LCG
AIMT

Lisanti Capital Growth’s Aimmune Therapeutics AIMT Stock Holding History

Lisanti Capital Growth’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-163,958
Closed -$5.49M – 159
2019
Q4 		$5.49M Buy
163,958
+116,368
+245% +$3.25M 1.46% 25
2019
Q3 		$997K Buy
+47,590
New +$972K 0.33% 79

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Lisanti Capital Growth's AIMT Position: Q1 2020 in Review

Lisanti Capital Growth sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 163,958 shares — an estimated $5.49M sold.

Lisanti Capital Growth first reported a position in AIMT in Q3 2019 and held it in 2 quarters. The position peaked at $5.49M in Q4 2019. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

  • Lisanti Capital Growth reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Lisanti Capital Growth sold 163,958 Aimmune Therapeutics shares in Q1 2020, an estimated $5.49M.
  • Lisanti Capital Growth first reported a position in Aimmune Therapeutics in Q3 2019 and held it in 2 quarters.
  • Lisanti Capital Growth's Aimmune Therapeutics position peaked at $5.49M in Q4 2019.
  • 161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on Lisanti Capital Growth's 13F filing for Q1 2020, filed 11 May 2020.